| HOME | SITEMAP | REGISTRATION | FEEDBACK | ALL COURSES | MY CME |
|
CME Activity Information |
|
|
Release Date: |
June 30, 2008 |
|
Date Credit Expires: |
June 30, 2010 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here to learn more about our review process. |
|
Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
Study the educational activity
Complete the CME quiz and evaluation
After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate
*The CME quiz and evaluation must be completed by June 30, 2010, in order to receive the credit or participation certificate.
Target Audience
Physicians
who wish to advance their current knowledge of clinical cancer
medicine in pediatric oncology and are involved in providing patient
care in a cancer care environment.
Learning
Objectives
After completing this course, the reader should be able to:
Describe the characteristics of pediatric patients who have enrolled in phase I trials over the past decade.
Describe the relationship between enrollment characteristics and the risk for toxicity in a phase I trial.
Identify the potential risks and benefits for pediatric patients with refractory solid tumors in phase I trials.
Accreditation and Credit Designation
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint sponsorship of
the School of Medicine of The University of North Carolina at Chapel
Hill and The
Oncologist.
The School of Medicine of The University of North Carolina at Chapel
Hill is accredited by the ACCME to provide continuing medical
education for physicians.
The School of Medicine of The
University of North Carolina at Chapel Hill designates this
educational activity for a maximum of 1.00 AMA
PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
Disclosure
Policy
In compliance with the ACCME Standards of Commercial Support, it is the policy of the School of Medicine of The University of North Carolina at Chapel Hill to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.
All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. Editors' disclosures are published annually online, whereas reviewers' disclosures are held in confidence within the Editorial Office. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.
Content Review
Author Disclosure(s)
The
authors disclose that this
article discusses the investigational use of the following products
in pediatric phase I trials: docetaxel, ixabepilone, paclitaxel,
pyrazoloacridine, tomudex, 9-cis-retinoic acid, ATRA/INF-
2A,
phenylacetate, phenylbutyrate, and temozolomide/O6benzylguanine,
provided by CTEP; lipodox, provided by Elan Pharmaceuticals;
tipifarnib, provided by Janssen Research Foundation; ABT-751,
provided by Abbott Laboratories; SU101, provided by SUGEN;
lobradimil, provided by Alkermes; and tariquidar, provided by Xenova.
AeRang Kim, M.D.
Credentials:
Clinical
Fellow, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Elizabeth Fox, M.D., MSCR
Credentials:
Principal
Investigator, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Katherine Warren, M.D.
Credentials:
Principal
Investigator, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Susan M. Blaney, M.D.
Credentials:
Professor
of Pediatrics, Texas Children's Cancer Center, Baylor College of
Medicine, Houston, Texas, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Stacey L. Berg, M.D.
Credentials:
Professor
of Pediatrics, Texas Children's Cancer Center, Baylor College of
Medicine, Houston, Texas, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Peter C. Adamson, M.D.
Credentials:
Chief,
Division of Clinical Pharmacology & Therapeutics, Children's
Hospital of Philadelphia, Philadelphia, Pennsylvania,
USA
Disclosures:
The
author has indicated no relevant commercial relationships.
Madeleine Libucha
Credentials:
Project
Manager, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Elena Byrley
Credentials:
Project
Manager, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Frank M. Balis, M.D.
Credentials:
Clinical
Director, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Brigitte C. Widemann, M.D.
Credentials:
Principal
Investigator, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, Maryland, USA.
Disclosures:
The
author has indicated no relevant commercial relationships.
Section Editors Disclosures
Susan M. Blaney, M.D., and Ross Pinkerton, M.D., have disclosed no financial relationships relevant to the content of this article.
CME Activity Director Disclosure
Frank M. Balis, MD, CME Activity Director, has disclosed no financial relationships relevant to the content of this article.
Independent Peer Reviewers, and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.
Commercial Support
Non-governmental
supporters of this activity: Merck and sanofi-aventis
Hardware/Software
Requirements
The
Oncologist CME
Online
supports the following browsers: Current production versions of
Opera, Safari, Firefox, Lynx and Mozilla; Netscape 6.1 and above, and
Explorer 6.0 and above. The Macintosh version of Explorer was
discontinued in June 2003, and is not supported.
Other
Links
Disclaimer
Privacy
statement
Correspondence
The
Oncologist
CME Online
c/o
AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North
Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email:
angela.davies{at}ucdmc.ucdavis.edu
| HOME | SITEMAP | REGISTRATION | FEEDBACK | ALL COURSES | MY CME |